Form 4: Oric Pharmaceuticals Director, Lori Anne Kunkel, Reports Stock Option Grant

Director Lori Anne Kunkel reports the acquisition of stock options in Oric Pharmaceuticals.

Summary

• On June 14, 2024, Lori Anne Kunkel, a director of Oric Pharmaceuticals, filed a Form 4.
• The report details the grant of stock options to Kunkel on June 12, 2024.
• Kunkel was granted options to purchase 25,600 shares of Oric Pharmaceuticals common stock at an exercise price of $7.90.
• The options vest on the earlier of June 12, 2025, or the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant.
• Following the transaction, Kunkel directly owns 25,600 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock option grant, which is a neutral event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.

Key Dates